{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huang YY"],"funding":["Ministry of Science and Technology, Taiwan"],"pagination":["e0217384"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6602418"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(7)"],"pubmed_abstract":["[18F]T807 is a potent tau protein imaging agent. In order to fulfill the demand from preclinical and clinical studies, we developed an automated one-pot two-step synthesis of this potent tau imaging agent and studied its stability, and dosimetry in mice and monkeys. We also conducted a preliminary study of this imaging agent in humans. Using this one-pot two-step method, the radiochemical yield (RCY) of [18F]T807 was 20.5 ± 6.1% (n = 15) at the end of bombardment (EOB) in a synthesis time of 70±5 min. The chemical and radiochemical purities were >90% and the specific activities were 151 ± 52 GBq/μmol. The quality of [18F]T807 synthesized by this method met the U.S. Pharmacopoeia (USP) criteria. The stability test showed that the [18F]T807 injection was stable at room temperature for up to "],"journal":["PloS one"],"pubmed_title":["An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans."],"pmcid":["PMC6602418"],"funding_grant_id":["MOST 106-2321-B-002-018"],"pubmed_authors":["Cheng CY","Ma KH","Huang YY","Chiu CH","Yen RF","Hsin LW","Tzen KY","Shiue CY","Wu CH","Chiu MJ","Tsai CL","Hsieh HY"],"additional_accession":[]},"is_claimable":false,"name":"An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans.","description":"[18F]T807 is a potent tau protein imaging agent. In order to fulfill the demand from preclinical and clinical studies, we developed an automated one-pot two-step synthesis of this potent tau imaging agent and studied its stability, and dosimetry in mice and monkeys. We also conducted a preliminary study of this imaging agent in humans. Using this one-pot two-step method, the radiochemical yield (RCY) of [18F]T807 was 20.5 ± 6.1% (n = 15) at the end of bombardment (EOB) in a synthesis time of 70±5 min. The chemical and radiochemical purities were >90% and the specific activities were 151 ± 52 GBq/μmol. The quality of [18F]T807 synthesized by this method met the U.S. Pharmacopoeia (USP) criteria. The stability test showed that the [18F]T807 injection was stable at room temperature for up to ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2025-04-22T20:30:17.632Z","creation":"2019-07-25T07:01:33Z"},"accession":"S-EPMC6602418","cross_references":{"pubmed":["31260447"],"doi":["10.1371/journal.pone.0217384"]}}